Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

被引：0
|
作者：
Fowler, Nathan H. [1 ]
Kahanic, Stephen P. [2 ]
Forero, Andres [3 ]
Munteanu, Mihaela C. [4 ]
Davis, Glen L. [4 ]
Brown, Peter [4 ]
Van Den Neste, Eric [5 ]
Offner, Fritz C. [6 ]
Bron, Dominique [7 ]
Czuczman, Myron S. [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Siouxland Hematol Oncol, Sioux City, IA USA
[3] Univ Alabama, Birmingham, AL USA
[4] Cephalon Inc, Frazer, PA USA
[5] Clin Univ UCL St Luc, Brussels, Belgium
[6] Univ Hosp Ghent, Ghent, Belgium
[7] Inst Jules Bordet, B-1000 Brussels, Belgium
[8] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [41] Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial
    Ujjani, Chaitra
    Cheson, Bruce
    FUTURE ONCOLOGY, 2011, 7 (01) : 9 - 14
  • [42] Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
    Dennie, Trevor W.
    Kolesar, Jill M.
    CLINICAL THERAPEUTICS, 2009, 31 : 2290 - 2311
  • [43] Complete response rates with lenalidonide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.
    Fowler, N. H.
    McLaughlin, P.
    Hagemeister, F. B.
    Kwak, L. W.
    Fanaie, M. A.
    Neelapu, S. S.
    Fayad, L.
    Orlowski, R. Z.
    Wang, M.
    Samaniego, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma
    Fowler, N. H.
    McLaughlin, P.
    Kwak, L.
    Hagemeister, F.
    Fanale, M.
    Fayad, L.
    Pro, B.
    Samaniego, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
    Ogawa, Y
    Hotta, T
    Tobinai, K
    Watanabe, T
    Sasaki, Y
    Minami, H
    Morishima, Y
    Ogura, M
    Seriu, T
    ANNALS OF ONCOLOGY, 2006, 17 (02) : 330 - 333
  • [46] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [47] Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
    Gopal, Ajay K.
    Greenbaum, Adam
    Lynch, Ryan C.
    Warren, Edus H.
    Ujjani, Chaitra S.
    Shadman, Mazyar
    Smith, Stephen D.
    Till, Brian G.
    Fromm, Jonathan R.
    Shustov, Andrei R.
    Wu, Qian Vicky
    Menon, Manoj P.
    BLOOD, 2019, 134
  • [48] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Dang, NH
    Hagemeister, FB
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Jones, D
    Samuels, B
    Samaniego, F
    Younes, A
    Wang, M
    Goy, A
    Rodriguez, MA
    Walker, PL
    Arredondo, Y
    Tong, AT
    Fayad, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) : 4095 - 4102
  • [49] Results of a phase I study of bendamustine in combination with ofatumumab, carboplatin, and etoposide (BOCE) for refractory or relapsed aggressive B-cell non-Hodgkin lymphomas (NHL).
    Gaballa, Sameh
    Palmisiano, Neil David
    Asija, Aakanksha
    Chapman, Andrew E.
    Cloud, Jennifer K.
    Filicko-O'Hara, Joanne E.
    Rose, Lewis J.
    Ramirez, Michael J.
    Alpdogan, Onder
    Flomenberg, Neal
    Pro, Barbara
    Gitelson, Elena
    Weiss, Mark Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Bendamustine A Review of its Use in the Management of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
    Garnock-Jones, Karly P.
    DRUGS, 2010, 70 (13) : 1703 - 1718
12345